Hackensack Meridian Living at Holmdel LLC

Hackensack Meridian Health is one of the largest integrated healthcare networks in New Jersey, with18 hospitals and more than 500 patient care locations, including ambulatory care centers, surgery centers, home health services, ambulance services, air medical transportation, rehabilitation centers, urgent care centers, physician practice locations, and a fitness and wellness center. The network has more than 35,000 team members and 7,000 physicians. Sameer Sethi, Hackensack Meridian Health SVP and chief AI and insights officer, spoke with MobiHealthNews about how much of its 2025 budget will be allocated for AI adoption? MobiHealthNews: Do you have plans on spending a percentage of your 2025 budget on AI? Sameer Sethi: We have been allocating an amount of budget to AI for quite a few years, at least for the two and a half years that I have been here. AI has been a separate cost center for me, which I manage. The evolution of that is what we call AI 2.0, because we have run through AI 1.0 in the past two and a half years that I have been here. When I came here, I helped develop an AI strategy, and we have learned and evolved from that. As a result of that, we have now developed our AI 2.0 strategy. That costs money. Without disclosing numbers, we have a higher allocation of budget. I started here as a data and analytics officer. I am now the chief AI officer. That is an investment and a commitment from the organization to take this further. So, we will be doing more with AI. My role here is AI but also RPA, robotics processing and automation. When you fuse that together we call that IPA, which is intelligence process automation. We take the concepts of AI and the concepts of automation and we put it together to best use. The evolution in addition to additional costs and, therefore, the use cases, are dependent on a lot of the successes. The successes being that in the last few years we have built a solid foundation that we can build AI on top of. We have hired the people, we trained them. We continue to hire and train them. And we have built a lot of use cases and have learned from that exercise and experience of what works and what does not work. MHN: What are your main focus areas regarding AI? Sethi: At first, we had three buckets: We will do things to bring in operational efficiency, we will build things to help decision support, and the third is we will build things that will build patient experience. From that we evolved. Now we have six focus areas, or buckets, for AI and automation. We will build AI to create personalized and equitable experiences, we will create AI to streamline administrative and clinical efficiencies, we will develop AI for capacity management and burnout alleviation, we will build AI for disease detection, and we will build AI for precision treatment and research and innovation. MHN: What are positive contributions of AI in healthcare, and what are some of your concerns related to AI? Sethi: AI is controversial. AI becomes controversial when people start to think of AI as one size fits all. It's not. It is similar to any other software. All this has to be fine-tuned and built to purpose. If you build AI to purpose then that controversy starts to go away. Part of the controversy around AI is: Is it wrong? Is this correct? That is one piece of this. There is another side of the controversy around what it does to the workforce. Does it take jobs away? AI is not going to take jobs away. It is going to take jobs away from people who do not use AI. When I'm asked this question, AI is not going to replace physicians, but AI will replace physicians that do not use AI. What we have seen is that AI is helping physicians. For example, when you go into a physician's office, the physician generally does not look at you eye-to-eye and is actually staring at the screen and reading something. What they are reading is your clinical information, which to some degree they should have time to do prior to coming into the room. There are a lot of pressures around seeing more patients every day, and these physicians don't get time to read the hundreds of lines of information that are available in a patient's EMR or clinical record. What we do with AI is we summarize that information for the clinician. Today, information is coming from your watch, your phone and heart rate monitors, and from five other doctors that you saw or the hundred doctors that you saw since you have been alive. All that data is a lot of data. It takes a lot of time for humans to process that data. That is where AI comes in. AI is helping them, it is not replacing them. AI is decision support. AI is helping a physician make a decision amongst all other noises that they have to deal with. Physicians are trained to do this; we are just making their jobs better. To me, the controversy is coming around understanding what AI is and how it should be used. If you educate people and train the models, and you train the end users, as you would with any other software, then the controversy for the most part goes away. We, as an organization, take AI governance very seriously. And when I say AI governance, it's not just building what needs to be built, but it is also the safety. We look at 108 different ways of what AI should and should not be. We have 13 domains that result in our 108-point check. That determines and looks at bias safety, security and privacy. We evaluate all of these things to remove more of that controversy. With these three things AI starts to become less controversial and very safe. MHN: Does AI have a bright future in hospitals and health systems? Sethi: I am personally committed and very optimistic that AI is going to make things better. I also want to point out that there is an element of cost. There are opportunities in healthcare. The cost of healthcare is tremendous. Our elderly population is increasing. Us, as a country overall, are not getting a whole lot healthier, and we require care, between the expensive cost of healthcare, plus the aging population, plus we are being more careful when diseases come around. We need help, and AI can help with those things. It doesn't solve those problems 100%. It doesn't become a doctor, but it can definitely take away certain things that today cost us a lot. So, I think that the avenues by which it is coming at us, unlike the internet, is really fast. We as a society need to spend more time educating ourselves, trying it out and giving it a chance. And if we do that, I think things will go a lot easier.

Presentations and publications from JTCC experts showcase research on treatment, interception, and prevention of blood cancers at American Society of Hematology conference. HACKENSACK, N.J., Dec. 6, 2024 /PRNewswire/ -- Researchers from Hackensack Meridian Health's (HMH) John Theurer Cancer Center, a research partner with Georgetown's Lombardi Comprehensive Cancer Center, an NCI-designated comprehensive cancer center, are presenting the latest data from their investigations in hematologic oncology at the 66th Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, California, from December 7-10, 2024. Continue Reading John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey. "The John Theurer Cancer Center is known for depth, breadth, and scope of expertise across hematologic oncology," said Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center (JTCC). "This year's presentations highlight new treatments that show promise for treating these diseases more effectively than standard therapies, as well as update the public as to our advancement in treatment of blood cancers that transcends all demographics of patient populations." Several of Dr. Goy's colleagues from the John Theurer Cancer Center will attend ASH representing the HMH network. At the event, the team will be on hand to speak on research from several, out of more than 70, ASH-accepted abstracts—first-authored or co-authored by JTCC/HMH researchers. Research topics fall along the lines of bone marrow transplantation, hematologic oncology, leukemia, lymphoma, multiple myeloma, and pediatric cancers, most prominently including: Bone Marrow Transplantation Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression Ezh2 and Intracellular Ca2+ Signals Interdependently Coordinate Gvhd and CAR T Cell Responses Ezh2 and Intracellular Ca2+ Signals Interdependently Coordinate Gvhd and CAR T Cell Responses Hematologic Oncology Lymphodepletion with Fludarabine/Cyclophosphamide Shows Higher Complete Response Rates Compared to Bendamustine Prior to CAR-T Therapy Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors Lymphoma 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial Inhibiting Tumor Cell CDK9 Reprograms Cell Death Pathways to Enhance Efficacy of CAR T Cell Therapy Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study Leukemia Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience Human IFN-α2- and PD-L1-Modified T Cells (αp-T cells) Inhibit Graft-Versus-Host Disease but Retain Anti-Leukemia Activity Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager Multiple Myeloma Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM) Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma Pediatric Cancers An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel About John Theurer Cancer Center at Hackensack University Medical Center Hackensack Meridian John Theurer Cancer Center at Hackensack University Medical Center is recognized as one of the Nation's premier cancer centers by U.S. News & World Report. The cancer center is a research partner with Georgetown's Lombardi Comprehensive Cancer Center, an NCI-designated comprehensive cancer center. They are also the largest and most comprehensive center dedicated to diagnosis, treatment, management, research, screening, and preventive care as well as survivorship of patients with all types of cancers in New Jersey. The 16 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 781-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities. The center recently expanded to Jersey Shore University Medical Center, serving patients in southern New Jersey and parts of Pennsylvania. Toms River Regional Cancer Center and Saint Joseph's Health are affiliated with the cancer center. For additional information, please visit SOURCE Hackensack Meridian John Theurer Cancer Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

DUBLIN--( BUSINESS WIRE )--The "Digital Transformation and Emerging Technologies in the Healthcare Industry 2024 Edition" report has been added to ResearchAndMarkets.com's offering. The report examines the progress of digital transformation in the pharmaceutical industry. It assesses the industry's preparedness to embrace innovation, explores the challenges and opportunities associated with digital transformation as well as highlights current and emerging trends in technology-related investments. The pharmaceutical industry is facing ongoing shifts driven by declining profit margins, increasing cost pressures, and the need to both replenish pipelines and maximize peak sales, all while adhering to strict regulatory and legislative requirements. Although adopting innovative technologies is seen as a key strategy to mitigate these challenges, the digitalization process is complex, time-consuming, and requires significant investment, along with sustained commitment and transparent dialogue with various stakeholders, including employees, investors, and regulators. The pharmaceutical industry is experiencing steady advancement in digital transformation. Mirroring 2023 survey findings, operations enablement and innovation was selected as the main scope of digital transformation in 2024. Optimism regarding the growth of digital transformation in their organizations reached record highs among the pharma industry professionals. In line with previous years' results, lack of specific skills and talents was selected as the top hinderance for digital transformation. Digital privacy and data security issues have ranked as the top concern associated with digital transformation, closely followed by cybersecurity concerns. Strong leadership was regarded as the key driver for a successful digital transformation. Pharma industry professionals are prioritizing artificial intelligence (AI) for current and future investments. Digital transformation is a must for maintaining competitive advantage in the pharmaceutical industry. Scope Benchmark the level of business readiness and technology adoption. Gain a deeper understanding of the business functions affected the most by digital transformation. Identify and assess barriers to adopting emerging technologies. Define the critical requirements for success. Determine the importance of emerging technologies to the pharmaceutical industry. Evaluate current levels of investment and identity both present and future investment priorities. Analyze the impact of COVID-19, inflation, and other factors on digitalization efforts. Explore the impact of emerging technologies on the pharmaceutical value chain. Assess the role of digital transformation in sustaining competitive advantage. Reasons to Buy Stay up to date on the scope, challenges, and essentials for the digital transformation within the healthcare industry. Explore how innovations are transforming the healthcare industry and what impact on the sector these technologies will have in the near future. Develop and design your corporate strategies through an in-house expert analysis of the key factors of digital transformation and emerging technology in the healthcare sector. Develop business strategies by understanding the key factors of digital transformation and emerging technology in the healthcare sector. Identify emerging industry trends in the uptake of emerging technologies to gain a competitive advantage. Key Topics Covered: Study Design Key Findings Overview of Digital Transformation Digital Transformation Strategies Digital Transformation Objectives Obstacles to Digital Transformation Concerns Associated with Digital Transformation Necessities for Digital Transformation Emerging Technologies - Investment Trends Artificial Intelligence Case Studies Summary of Key Findings Appendix Competitive Landscape Amgen AB BenevolentAI Ltd Biolexis Therapeutics Inc Cellix Biosciences Inc Eli Lilly and Co Generate Biomedicines Inc Google Cloud Platform Hackensack Meridian Health Inc Healx Ltd Highmark Health InSilico Medicine Mount Sinai Health System Novartis AG Recursion Pharmaceuticals Inc For more information about this report visit https://www.researchandmarkets.com/r/r3umsv About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.